Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for Parenteral Nutrition Induced Liver Injury
NCT01845116Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2010
- Primary completion
- Jul 2020
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD), sponsored by Wake Forest University Health Sciences. Started Jul 2010; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT01845116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01845116.